Fuda Cancer Hospital
| China | Turkey | Austria | |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $6,500 | from $40,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
China utilizes cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy as the primary protocol for carcinomatosis. The procedure involves removing visible tumors before circulating heated medicine into the abdominal cavity. This integrated approach often combines Western surgical standards with traditional therapies to manage side effects and inflammation.
Bookimed Expert Insight: Chinese oncology clinics like Fuda Cancer Hospital offer alternatives to standard systemic chemotherapy. These centers specialize in combining hyperthermic treatments with over 10 types of minimally invasive therapies. This approach is useful for patients seeking options beyond traditional aggressive resection. Accreditation by Joint Commission International ensures these facilities follow standardized protocols for international patients from over 100 countries.
Patient Consensus: Patients emphasize that this aggressive surgery is not a universal solution for everyone. Success depends heavily on receiving a second opinion to verify disease burden and primary tumor type.
Beijing Shijitan Hospital and Fuda Cancer Hospital lead Chinas treatment for peritoneal carcinomatosis. These centers utilize cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Specialized teams manage advanced abdominal malignancies. JCI-accredited facilities often provide integrated multi-modal care for international patients.
Bookimed Expert Insight: China is a unique destination for late-stage abdominal cancers. Centers like Fuda Cancer Hospital have served over 30,000 international patients. Clinical teams often accept advanced cases that other global institutions may decline. This high volume allows surgeons to maintain proficiency in complex debulking procedures.
Patient Consensus: Patients note that Chinese doctors often consider surgery for cases deemed inoperable elsewhere. It is important to provide full pathology reports and PET scans before travel.
Traditional Chinese Medicine (TCM) is integrated into carcinomatosis care strictly as a supportive therapy. Chinese oncology centers combine herbal formulas and acupuncture with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This integrative approach aims to reduce fluid buildup and alleviate chemotherapy side effects. TCM never replaces surgical or interventional treatments.
Bookimed Expert Insight: Data shows leading facilities like Fuda Cancer Hospital emphasize minimally invasive technologies over traditional chemo. They utilize NanoKnife and cryosurgery alongside supportive care for advanced stages. This suggests that in China, the value of TCM lies in helping patients physically tolerate these high-tech interventions. Integrating TCM within JCI-accredited hospitals ensures better safety than using standalone alternative clinics.
Patient Consensus: Patients note that integrated hospital teams are more trustworthy for managing herb-drug interactions. They highlight the importance of using TCM specifically for appetite and comfort rather than seeking it as a primary cure.
Chinese oncology centers utilize domestically developed, proprietary platforms like the BR-TRG series for HIPEC delivery. These advanced systems function as high-precision thermal perfusion units. They maintain intra-abdominal temperatures at a precise 43.0°C. This level of control optimizes chemotherapy effectiveness while protecting healthy tissue.
Bookimed Expert Insight: While Chinese manufacturers dominate the domestic market, the real differentiator is clinical volume. Fuda Cancer Hospital has served over 30,000 international patients. This high volume allows surgeons to master proprietary tools like microwave hyperthermia. This experience often leads to more refined, personalized perfusion protocols than standard settings.
Patient Consensus: Patients note it is vital to confirm if a clinic performs full cytoreductive surgery alongside HIPEC. Many emphasize asking for specific data on surgeon volume and perfusion temperatures rather than just focusing on the machine brand.
Oncology centers in China offer biological and targeted therapies alongside CRS-HIPEC for peritoneal carcinomatosis. These include PARP inhibitors for ovarian cancer and angiogenesis inhibitors like Bevacizumab. Specialized facilities often integrate immunotherapy with minimally invasive technologies. Procedures like PIPAC provide localized delivery for unresectable cases.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital treat over 30,000 international patients. They often combine standard HIPEC with unique techniques like NanoKnife and cryosurgery. This multi-modal approach helps manage late-stage cases that are often ineligible for surgery. Specialists like Prof. Liu Shi Xin emphasize precision radiotherapy for abdominal malignancies alongside systemic drugs.
Patient Consensus: Patients note that targeted therapy isn't automatic and requires specific genetic testing for mutations like KRAS or HER2. Many advise confirming if a center has integrated medical oncology teams before starting treatment.
International patients receive carcinomatosis treatment in China at JCI-accredited oncology centers and university hospitals. These facilities specialize in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Treatment integrates Western surgical protocols with advanced ablation technologies like NanoKnife to target solid tumor metastases.
Bookimed Expert Insight: China offers a unique advantage for patients with specific solid tumor markers because it leads in CAR-T therapy trials for gastric and colorectal carcinomatosis. Hospitals like Xiamen Humanity Hospital utilize elite experts like Dr. Liu Shi Xin, who holds a State Council Special Government Allowance for oncology. Patients should prioritize clinics with dedicated peritoneal surface oncology departments rather than general cancer wards.
Patient Consensus: Patients emphasize the need for medical records to be pre-reviewed by Chinese surgical teams before traveling. They note that having on-site English-speaking coordinators and translators is vital for understanding pathology results and post-operative instructions.
Final treatment decisions for carcinomatosis in China result from shared decision-making between patients, families, and multidisciplinary medical teams. While competent adults maintain the legal right to consent, cultural norms often prioritize family consensus. Clinical experts provide specialized guidance on complex interventions like HIPEC or NanoKnife surgery.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows that treating 30,000+ international patients requires bridging different decision-making styles. While Western patients often decide individually, Chinese specialists are accustomed to detailed consultations with the family first. Choosing a JCI-accredited facility ensures that these family-driven discussions still respect international standards for informed patient consent.
Patient Consensus: Patients note that doctors in China may speak directly to relatives before sharing specific details with the patient. It is common for senior surgeons to lead the decision when choosing between aggressive surgery or palliative care.